



PURC, a quality improvement initiative, brings urology practices together in a physician-led data-sharing collaborative aimed at advancing the quality of prostate cancer diagnosis and care.

2017 AUA Risk Stratification for Localized Prostate Cancer	
Very Low Risk	PSA < 10 ng/ml AND Grade Group 1 AND clinical stage T1 - T2a AND <34% of biopsy cores positive AND no core with >50% involved, AND PSA density < 0.15 ng/ml/cc
Low Risk	PSA < 10 ng/ml AND Grade Group 1 AND clinical stage T1 - T2
Favorable Intermediate Risk	Grade Group 1 (with PSA 10 - <20) OR Grade Group 2 (with PSA < 10)
Unfavorable Intermediate Risk	Grade Group 2 (with either PSA 10 - <20 or clinical stage T2b - c) OR Grade Group 3 (with PSA < 20)
High	PSA > 20 ng/ml OR Grade Group 4 - 5 OR clinical stage > T3*

*Clinical stage T3 cancer is considered locally advanced.

Imaging Recommendations by Risk Category 2017 AUA Recommendations*

Risk Category	Axial Imaging	Bone Scan
Very Low	+/- MRI	None
Low	+/- MRI	None
Favorable Intermediate	+/- MRI	None
Unfavorable Intermediate	CT or MRI	Yes
High	CT or MRI	Yes



For more information, please contact Claudette Fonshell at cfonshell@hcfonline.org or 215-575-3747.

*Source: [http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-\(aua/astro/suo-guideline-2017\)](http://www.auanet.org/guidelines/clinically-localized-prostate-cancer-new-(aua/astro/suo-guideline-2017))